Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.
Elham Nasri, MD
Advertisement
Articles by Elham Nasri, MD
Elham Nasri, MD, fellow, Bone and Soft Tissue Pathology, University of Florida, discusses risk stratification in osteosarcoma.
Advertisement
Latest Updated Articles
Dr. Nasri on Risk Stratification in OsteosarcomaPublished: October 16th 2019 | Updated:
Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in OsteosarcomaPublished: January 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5